Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | — | -$1.06M | -$836K |
| Net income | — | $2.55M | $1.06M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | — | -$672K | -$565K |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total assets | $70.5M | $73.8M | $12.1M |
| Total liabilities | $715K | $1.51M | $4.06M |
| Shareholders' equity | -$134K | -$1.48M | -$4.06M |
| Retained earnings | -$134K | -$1.48M | -$4.06M |
| Shares (wtd avg diluted) | 2.13M | 2.13M | 2.13M |
Every figure is extracted from Aimei Health Technology Co., Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.